FDA Reviews BioMarin's VOXZOGO for Full Achondroplasia Approval

The U.S. Food and Drug Administration has accepted BioMarin's supplemental New Drug Application for VOXZOGO, a treatment for children with achondroplasia. This application seeks full approval and is supported by extensive long-term safety and efficacy data, including adult height outcomes. A decision on the application is anticipated by February 28, 2027.